China's GVP requires drug marketing authorization holders (MAHs) and drug registration applicants to establish and improve pharmacovigilance (PV) systems as well as conduct pharmacovigilance activities compliantly. Pharmacovigilance activities are subject to national and provincial medical products' inspections according to the Pharmacovigilance Inspection Guidelines.
Related: Decoding China's Good Pharmacovigilance Practices (GVP)